PMC:7299399 / 6678-7573 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T22","span":{"begin":109,"end":114},"obj":"Body_part"},{"id":"T23","span":{"begin":341,"end":346},"obj":"Body_part"},{"id":"T24","span":{"begin":430,"end":435},"obj":"Body_part"},{"id":"T25","span":{"begin":563,"end":567},"obj":"Body_part"},{"id":"T26","span":{"begin":581,"end":586},"obj":"Body_part"},{"id":"T27","span":{"begin":623,"end":630},"obj":"Body_part"},{"id":"T28","span":{"begin":631,"end":638},"obj":"Body_part"},{"id":"T29","span":{"begin":657,"end":660},"obj":"Body_part"},{"id":"T30","span":{"begin":675,"end":683},"obj":"Body_part"}],"attributes":[{"id":"A22","pred":"fma_id","subj":"T22","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A23","pred":"fma_id","subj":"T23","obj":"http://purl.org/sig/ont/fma/fma68877"},{"id":"A24","pred":"fma_id","subj":"T24","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma67498"},{"id":"A27","pred":"fma_id","subj":"T27","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A28","pred":"fma_id","subj":"T28","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A29","pred":"fma_id","subj":"T29","obj":"http://purl.org/sig/ont/fma/fma67847"},{"id":"A30","pred":"fma_id","subj":"T30","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"As shown in Figure 1, the first events of the infection (i.e., the interactions of the virus with the target cells expressing ACE2) are in the process of being elucidated at the molecular level. However, as patients suffering from severe symptoms—which usually develop only after several days or a week—already bear a high viral load in the lungs, there is a pressing need for strategies not only to prevent infection of the host cells but also to attack pre-existing persistent viruses and to prevent life-threatening processes, such as hyperinflammation in the lung and multiple-organ failure.25 Notably, a comprehensive protein–protein interaction (PPI) map of most viral proteins with the human proteome has been established to provide potentially novel targets for treatment employing already U.S. Food and Drug Administration (FDA)-approved drugs via a process known as drug repurposing.26"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T9","span":{"begin":563,"end":567},"obj":"Body_part"},{"id":"T10","span":{"begin":581,"end":586},"obj":"Body_part"}],"attributes":[{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A10","pred":"uberon_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"}],"text":"As shown in Figure 1, the first events of the infection (i.e., the interactions of the virus with the target cells expressing ACE2) are in the process of being elucidated at the molecular level. However, as patients suffering from severe symptoms—which usually develop only after several days or a week—already bear a high viral load in the lungs, there is a pressing need for strategies not only to prevent infection of the host cells but also to attack pre-existing persistent viruses and to prevent life-threatening processes, such as hyperinflammation in the lung and multiple-organ failure.25 Notably, a comprehensive protein–protein interaction (PPI) map of most viral proteins with the human proteome has been established to provide potentially novel targets for treatment employing already U.S. Food and Drug Administration (FDA)-approved drugs via a process known as drug repurposing.26"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T38","span":{"begin":46,"end":55},"obj":"Disease"},{"id":"T39","span":{"begin":408,"end":417},"obj":"Disease"},{"id":"T40","span":{"begin":572,"end":594},"obj":"Disease"}],"attributes":[{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A39","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A40","pred":"mondo_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/MONDO_0043726"}],"text":"As shown in Figure 1, the first events of the infection (i.e., the interactions of the virus with the target cells expressing ACE2) are in the process of being elucidated at the molecular level. However, as patients suffering from severe symptoms—which usually develop only after several days or a week—already bear a high viral load in the lungs, there is a pressing need for strategies not only to prevent infection of the host cells but also to attack pre-existing persistent viruses and to prevent life-threatening processes, such as hyperinflammation in the lung and multiple-organ failure.25 Notably, a comprehensive protein–protein interaction (PPI) map of most viral proteins with the human proteome has been established to provide potentially novel targets for treatment employing already U.S. Food and Drug Administration (FDA)-approved drugs via a process known as drug repurposing.26"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T64","span":{"begin":87,"end":92},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T65","span":{"begin":109,"end":114},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T66","span":{"begin":296,"end":297},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T67","span":{"begin":316,"end":317},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T68","span":{"begin":341,"end":346},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T69","span":{"begin":357,"end":358},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T70","span":{"begin":430,"end":435},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T71","span":{"begin":479,"end":486},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T72","span":{"begin":563,"end":567},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T73","span":{"begin":563,"end":567},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T74","span":{"begin":581,"end":586},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T75","span":{"begin":607,"end":608},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T76","span":{"begin":693,"end":698},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T77","span":{"begin":708,"end":711},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T78","span":{"begin":857,"end":858},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"As shown in Figure 1, the first events of the infection (i.e., the interactions of the virus with the target cells expressing ACE2) are in the process of being elucidated at the molecular level. However, as patients suffering from severe symptoms—which usually develop only after several days or a week—already bear a high viral load in the lungs, there is a pressing need for strategies not only to prevent infection of the host cells but also to attack pre-existing persistent viruses and to prevent life-threatening processes, such as hyperinflammation in the lung and multiple-organ failure.25 Notably, a comprehensive protein–protein interaction (PPI) map of most viral proteins with the human proteome has been established to provide potentially novel targets for treatment employing already U.S. Food and Drug Administration (FDA)-approved drugs via a process known as drug repurposing.26"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T24","span":{"begin":623,"end":630},"obj":"Chemical"},{"id":"T25","span":{"begin":631,"end":638},"obj":"Chemical"},{"id":"T26","span":{"begin":652,"end":655},"obj":"Chemical"},{"id":"T28","span":{"begin":675,"end":683},"obj":"Chemical"},{"id":"T29","span":{"begin":847,"end":852},"obj":"Chemical"},{"id":"T30","span":{"begin":876,"end":880},"obj":"Chemical"}],"attributes":[{"id":"A24","pred":"chebi_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A25","pred":"chebi_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A26","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_53266"},{"id":"A27","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_60614"},{"id":"A28","pred":"chebi_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A29","pred":"chebi_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A30","pred":"chebi_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"As shown in Figure 1, the first events of the infection (i.e., the interactions of the virus with the target cells expressing ACE2) are in the process of being elucidated at the molecular level. However, as patients suffering from severe symptoms—which usually develop only after several days or a week—already bear a high viral load in the lungs, there is a pressing need for strategies not only to prevent infection of the host cells but also to attack pre-existing persistent viruses and to prevent life-threatening processes, such as hyperinflammation in the lung and multiple-organ failure.25 Notably, a comprehensive protein–protein interaction (PPI) map of most viral proteins with the human proteome has been established to provide potentially novel targets for treatment employing already U.S. Food and Drug Administration (FDA)-approved drugs via a process known as drug repurposing.26"}

{"project":"LitCovid-sentences","denotations":[{"id":"T31","span":{"begin":0,"end":194},"obj":"Sentence"},{"id":"T32","span":{"begin":195,"end":802},"obj":"Sentence"},{"id":"T33","span":{"begin":803,"end":895},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"As shown in Figure 1, the first events of the infection (i.e., the interactions of the virus with the target cells expressing ACE2) are in the process of being elucidated at the molecular level. However, as patients suffering from severe symptoms—which usually develop only after several days or a week—already bear a high viral load in the lungs, there is a pressing need for strategies not only to prevent infection of the host cells but also to attack pre-existing persistent viruses and to prevent life-threatening processes, such as hyperinflammation in the lung and multiple-organ failure.25 Notably, a comprehensive protein–protein interaction (PPI) map of most viral proteins with the human proteome has been established to provide potentially novel targets for treatment employing already U.S. Food and Drug Administration (FDA)-approved drugs via a process known as drug repurposing.26"}

{"project":"LitCovid-PubTator","denotations":[{"id":"144","span":{"begin":126,"end":130},"obj":"Gene"},{"id":"145","span":{"begin":207,"end":215},"obj":"Species"},{"id":"146","span":{"begin":693,"end":698},"obj":"Species"},{"id":"147","span":{"begin":46,"end":55},"obj":"Disease"},{"id":"148","span":{"begin":408,"end":417},"obj":"Disease"},{"id":"149","span":{"begin":572,"end":594},"obj":"Disease"}],"attributes":[{"id":"A144","pred":"tao:has_database_id","subj":"144","obj":"Gene:59272"},{"id":"A145","pred":"tao:has_database_id","subj":"145","obj":"Tax:9606"},{"id":"A146","pred":"tao:has_database_id","subj":"146","obj":"Tax:9606"},{"id":"A147","pred":"tao:has_database_id","subj":"147","obj":"MESH:D007239"},{"id":"A148","pred":"tao:has_database_id","subj":"148","obj":"MESH:D007239"},{"id":"A149","pred":"tao:has_database_id","subj":"149","obj":"MESH:D009102"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"As shown in Figure 1, the first events of the infection (i.e., the interactions of the virus with the target cells expressing ACE2) are in the process of being elucidated at the molecular level. However, as patients suffering from severe symptoms—which usually develop only after several days or a week—already bear a high viral load in the lungs, there is a pressing need for strategies not only to prevent infection of the host cells but also to attack pre-existing persistent viruses and to prevent life-threatening processes, such as hyperinflammation in the lung and multiple-organ failure.25 Notably, a comprehensive protein–protein interaction (PPI) map of most viral proteins with the human proteome has been established to provide potentially novel targets for treatment employing already U.S. Food and Drug Administration (FDA)-approved drugs via a process known as drug repurposing.26"}

{"project":"2_test","denotations":[{"id":"32519842-32325025-158462","span":{"begin":595,"end":597},"obj":"32325025"}],"text":"As shown in Figure 1, the first events of the infection (i.e., the interactions of the virus with the target cells expressing ACE2) are in the process of being elucidated at the molecular level. However, as patients suffering from severe symptoms—which usually develop only after several days or a week—already bear a high viral load in the lungs, there is a pressing need for strategies not only to prevent infection of the host cells but also to attack pre-existing persistent viruses and to prevent life-threatening processes, such as hyperinflammation in the lung and multiple-organ failure.25 Notably, a comprehensive protein–protein interaction (PPI) map of most viral proteins with the human proteome has been established to provide potentially novel targets for treatment employing already U.S. Food and Drug Administration (FDA)-approved drugs via a process known as drug repurposing.26"}